Literature DB >> 33956427

Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery.

Samuel Obeng1,2, Takato Hiranita2, Francisco León3, Lance R McMahon2, Christopher R McCurdy1,4.   

Abstract

Because of the problems associated with opioids, drug discovery efforts have been employed to develop opioids with reduced side effects using approaches such as biased opioid agonism, multifunctional opioids, and allosteric modulation of opioid receptors. Receptor targets such as adrenergic, cannabinoid, P2X3 and P2X7, NMDA, serotonin, and sigma, as well as ion channels like the voltage-gated sodium channels Nav1.7 and Nav1.8 have been targeted to develop novel analgesics. Several enzymes, such as soluble epoxide hydrolase, sepiapterin reductase, and MAGL/FAAH, have also been targeted to develop novel analgesics. In this review, old and recent targets involved in pain signaling and compounds acting at these targets are summarized. In addition, strategies employed to reduce side effects, increase potency, and efficacy of opioids are also elaborated. This review should aid in propelling drug discovery efforts to discover novel analgesics.

Entities:  

Year:  2021        PMID: 33956427     DOI: 10.1021/acs.jmedchem.1c00028

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  5-Oxopyrrolidine-3-carboxamides as Nav1.8 Inhibitors for Treating Pain Disorders, Cough Disorders, and Acute and Chronic Itch Disorders.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-04-14       Impact factor: 4.345

2.  Selective Serotonin Receptor Modulators for Use in the Treatment of Psychological Disorders.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2022-03-30       Impact factor: 4.345

3.  The Psychedelic Renaissance: Addressing Potential Adverse Effects in a Therapeutic Setting.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-11-08       Impact factor: 4.345

4.  Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-11-08       Impact factor: 4.345

5.  2-Oxooxazolidine-5-carboxamides as Nav1.8 Inhibitors for Treating Pain Disorders, Cough Disorders, and Acute and Chronic Itch Disorders.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-03-01       Impact factor: 4.345

Review 6.  Inhibition of NaV1.7: the possibility of ideal analgesics.

Authors:  Yutaka Kitano; Tsuyoshi Shinozuka
Journal:  RSC Med Chem       Date:  2022-08-01

7.  Targeting Nuclear Receptors for Chronic Inflammatory Pain: A Potential Alternative.

Authors:  Kristine Griffett
Journal:  ACS Pharmacol Transl Sci       Date:  2022-05-19

8.  3-Pyrrolidine-indole Derivatives as 5-HT2-Selective Receptor Modulators for the Potential Treatment of Mental Disorders.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2022-04-26       Impact factor: 4.632

9.  5-HT Receptor Modulators for Therapeutic Use in the Treatment of Obsessive-Compulsive Disorder and Other Psychological Disorders.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2022-04-20       Impact factor: 4.632

10.  Psychedelic Therapeutic: Potential Treatment for Headache Disorders.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-09-28       Impact factor: 4.632

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.